Dapagliflozin Efficacy and Action in PCOS
The purpose of this study is to assess the efficacy and safety of dapagliflozin on improving insulin resistance and hyperandrogenemia in obesity women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
DRUG: Dapagliflozin|DRUG: Placebo
Improvement in insulin resistance over 12 weeks, Change in insulin resistance assessed by insulin sensitivity index(HOMA-IR), Baseline and 12 weeks|Improvement in serum androgen level over 12 weeks, Change in androgen level assessed by free testosterone index(FAI), Baseline and 12 weeks
Change in AUC (area under a curve) of glucose and insulin during the oral glucose tolerant test (OGTT), Baseline to 12 week|Change in serum free testosterone(FT), Baseline to 12 week|Change in serum sex hormone binding globulin(SHBG), Baseline to 12 week|Net change in total testosterone (TT) level, Baseline and 12 weeks|Net change in dehydroepiandrosterone-sulfate(DHEAS) level, Baseline and 12 weeks|Net change in androstenedione(AD) level, Baseline and 12 weeks|Net change in luteinzing hormone(LH) level, Baseline and 12 weeks|Net change in waist circumference, Baseline to 12 week|Net Change in liver fat, Liver fat will be assessed by liver fibroscan., Baseline to 12 week|Change in ovulation rate assessed by serum progesterone, Baseline to 12 week|Net change in body weight, Baseline to 12 week|Net change in BMI, Baseline to 12 week|Net change in glucose, Baseline to 12 week
The purpose of this study is to assess the efficacy and safety of dapagliflozin on improving insulin resistance and hyperandrogenemia in obesity women with polycystic ovary syndrome.